Angelica herb supplement put to the test in prostate cancer patients
NCT ID NCT05375539
First seen Oct 01, 2025 · Last updated May 22, 2026 · Updated 28 times
Summary
This early-stage study looked at the safety of a single dose of an angelica herbal supplement (AGN-Cogni.Q) in 12 men aged 40 and older with prostate cancer. Researchers checked heart health and blood tests for any side effects, and measured how the body absorbs the supplement's active compounds. The goal was to gather initial safety and processing data, not to treat the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Penn State Cancer Institute
Hershey, Pennsylvania, 17033, United States
Conditions
Explore the condition pages connected to this study.